{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:53:26Z","timestamp":1787496806690,"version":"build-2736575974"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVES:<\/jats:title>\n                    <jats:p>Postoperative hypertension frequently occurs after surgery for congenital heart disease. Given safety concerns when using calcium channel blockers in infants along with the cost and side-effect profile of nitroprusside, we retrospectively assessed our experience of using nicardipine and nitroprusside for postoperative blood pressure control in infants who underwent surgery for congenital heart disease. We also investigated the cost difference between the medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DESIGN:<\/jats:title>\n                    <jats:p>This study was a single-center retrospective, pre-post chart review of patients who had surgery for congenital heart disease between 2016 and 2020. The primary aim was a noninferiority comparison of achievement of blood pressure goal at 1-hour post-initiation of an antihypertensive agent. Secondary comparisons included achievement of blood pressure goal at 2 hours after medication initiation, Vasoactive-Inotropic Score (VIS), and blood transfusion, crystalloid volume, and calcium needs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SETTING:<\/jats:title>\n                    <jats:p>Academic quaternary-care center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS:<\/jats:title>\n                    <jats:p>\n                      Infants under 1 year old who required treatment for hypertension with nitroprusside (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 71) or nicardipine (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 52) within 24 hours of surgery for congenital heart disease.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>INTERVENTIONS:<\/jats:title>\n                    <jats:p>None.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MEASUREMENTS AND MAIN RESULTS:<\/jats:title>\n                    <jats:p>\n                      We failed to identify any difference in proportion of patients that achieved blood pressure control at 1-hour after medication initiation (nitroprusside 52% vs. nicardipine 54%;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.86), with nicardipine noninferior to nitroprusside within a 15% margin. Of patients who did not achieve control at 1-hour post-medication initiation, receiving nicardipine was associated with blood pressure control at 2 hours post-medication initiation (79% vs. 38%;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      = 0.003). We also failed to identify an association between antihypertensive types and mean VIS scores, blood transfusion volumes, crystalloid volumes, and quantities of calcium administered. Index cost of using nitroprusside was 16 times higher than using nicardipine, primarily due to difference in wholesale cost.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>In our experience of achieving blood pressure control in infants after surgery for congenital heart disease (2016\u20132020), antihypertensive treatment with nicardipine was noninferior to nitroprusside. Furthermore, nicardipine use was significantly less expensive than nitroprusside. Our contemporary practice is therefore to use nicardipine in preference to nitroprusside.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/pcc.0000000000003469","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T10:02:54Z","timestamp":1706781774000},"page":"538-546","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Nicardipine or Nitroprusside for Postoperative Blood Pressure Control in Infants After Surgery for Congenital Heart Disease: Single-Center Retrospective Noninferiority and Cost Analysis, 2016\u20132020*"],"prefix":"10.1097","volume":"25","author":[{"given":"Rudolph J.","family":"Wong","sequence":"first","affiliation":[{"name":"Department of Cardiac Intensive Care, Medical City Children\u2019s Hospital, Dallas, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison L.","family":"Mruk","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Banner University Medical Center, Phoenix, AZ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Grimaldi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Intensive Care, Phoenix Children\u2019s Hospital, Phoenix, AZ."},{"name":"Department of Child Health, University of Arizona College of Medicine Phoenix, Phoenix, AZ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Intensive Care, Phoenix Children\u2019s Hospital, Phoenix, AZ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Mirea","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Phoenix Children\u2019s Hospital, Phoenix, AZ."},{"name":"Department of Biomedical Informatics, University of Arizona College of Medicine Phoenix, Phoenix, AZ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin P.","family":"Engelhardt","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Intensive Care, Phoenix Children\u2019s Hospital, Phoenix, AZ."},{"name":"Department of Child Health, University of Arizona College of Medicine Phoenix, Phoenix, AZ."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"R1-20250502","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/2150135117690104","article-title":"Treatment strategies for paradoxical hypertension following surgical correction of coarctation of the aorta in children.","volume":"8","author":"Roeleveld","year":"2017","journal-title":"World J Pediatr Congenit Heart Surg"},{"key":"R2-20250502","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00246-020-02448-2","article-title":"Pharmacologic control of blood pressure in infants and children.","volume":"41","author":"Tobias","year":"2020","journal-title":"Pediatr Cardiol"},{"key":"R3-20250502","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/0897190018776396","article-title":"Sodium nitroprusside as a hyperinflation drug and therapeutic alternatives.","volume":"31","author":"Cobb","year":"2018","journal-title":"J Pharm Pract"},{"key":"R4-20250502","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1056\/NEJMc1700244","article-title":"Nitroprusside and isoproterenol use after major price increases.","volume":"377","author":"Knot","year":"2017","journal-title":"N Engl J Med"},{"issue":"3_Suppl","key":"R5-20250502","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1177\/2048872618777919","article-title":"Clevidipine as a therapeutic and cost-effective alternative to sodium nitroprusside in patients with acute aortic syndromes.","volume":"9","author":"Alviar","year":"2020","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"R6-20250502","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.athoracsur.2017.05.035","article-title":"Use of nicardipine after cardiac operations is safe in children regardless of age.","volume":"105","author":"Stone","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"R7-20250502","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s00246-019-02113-3","article-title":"Nicardipine for the treatment of neonatal hypertension during extracorporeal membrane oxygenation.","volume":"40","author":"Liviskie","year":"2019","journal-title":"Pediatr Cardiol"},{"key":"R8-20250502","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s00246-003-0497-0","article-title":"Intravenous nicardipine for treatment of postcoarctectomy hypertension in children.","volume":"25","author":"Nakagawa","year":"2004","journal-title":"Pediatr Cardiol"},{"key":"R9-20250502","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/2150135115608815","article-title":"Nicardipine for hypertension following aortic coarctectomy or superior cavopulmonary anastomosis.","volume":"7","author":"Mastropietro","year":"2016","journal-title":"World J Pediatr Congenit Heart Surg"},{"key":"R10-20250502","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/21501351221080173","article-title":"Nicardipine is a safe, efficacious, and cost-effective antihypertensive for neonates and young infants undergoing cardiac surgery.","volume":"13","author":"Lushaj","year":"2022","journal-title":"World J Pediatr Congenit Heart Surg"},{"key":"R11-20250502","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/jocs.14513","article-title":"Sodium nitroprusside versus nicardipine for hypertension management after surgery: A systematic review and meta-analysis.","volume":"35","author":"Villarreal","year":"2020","journal-title":"J Card Surg"},{"key":"R12-20250502","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00467-006-0311-3","article-title":"Blood pressure in non-critically ill preterm and full-term neonates.","volume":"22","author":"Pejovic","year":"2007","journal-title":"Pediatr Nephrol"},{"key":"R13-20250502","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1540-8191.2000.tb00470.x","article-title":"Low systemic vascular resistance after cardiopulmonary bypass: Incidence, etiology, and clinical importance.","volume":"15","author":"Carrel","year":"2000","journal-title":"J Card Surg"},{"key":"R14-20250502","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12887-020-1972-y","article-title":"Risk factors for low cardiac output syndrome in children with congenital heart disease undergoing cardiac surgery: A retrospective cohort study.","volume":"20","author":"Du","year":"2020","journal-title":"BMC Pediatr"},{"key":"R15-20250502","first-page":"635","article-title":"Therapeutic interchange of clevidipine for sodium nitroprusside in cardiac surgery.","volume":"41","author":"Cruz","year":"2016","journal-title":"P T"}],"container-title":["Pediatric Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PCC.0000000000003469","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T13:17:29Z","timestamp":1746191849000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PCC.0000000000003469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/pcc.0000000000003469","relation":{},"ISSN":["1529-7535"],"issn-type":[{"value":"1529-7535","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}